| Year |
Citation |
Score |
| 2022 |
Tatsuoka J, Sano E, Hanashima Y, Yagi C, Yamamuro S, Sumi K, Hara H, Takada K, Kanemaru K, Komine-Aizawa S, Katayama Y, Yoshino A. Anti-tumor effects of perampanel in malignant glioma cells. Oncology Letters. 24: 421. PMID 36284648 DOI: 10.3892/ol.2022.13541 |
0.437 |
|
| 2022 |
Yagi C, Tatsuoka J, Sano E, Hanashima Y, Ozawa Y, Yoshimura S, Yamamuro S, Sumi K, Hara H, Katayama Y, Yoshino A. Anti‑tumor effects of anti‑epileptic drugs in malignant glioma cells. Oncology Reports. 48. PMID 36281939 DOI: 10.3892/or.2022.8431 |
0.521 |
|
| 2021 |
Miller SR, Abresch HE, Ulrich NJ, Sano EB, Demaree AH, Oman AR, Garber AI. Bacterial Adaptation by a Transposition Burst of an Invading IS Element. Genome Biology and Evolution. 13. PMID 34791212 DOI: 10.1093/gbe/evab245 |
0.313 |
|
| 2020 |
Hanashima Y, Sano E, Sumi K, Ozawa Y, Yagi C, Tatsuoka J, Yoshimura S, Yamamuro S, Ueda T, Nakayama T, Hara H, Yoshino A. Antitumor effect of lenalidomide in malignant glioma cell lines. Oncology Reports. PMID 32323826 DOI: 10.3892/or.2020.7543 |
0.475 |
|
| 2019 |
Yoshimura S, Sano E, Hanashima Y, Yamamuro S, Sumi K, Ueda T, Nakayama T, Hara H, Yoshino A, Katayama Y. IFN‑β sensitizes TRAIL‑induced apoptosis by upregulation of death receptor 5 in malignant glioma cells. Oncology Reports. 42: 2635-2643. PMID 31638255 DOI: 10.3892/or.2019.7383 |
0.344 |
|
| 2019 |
Makita K, Hara H, Sano E, Okamoto Y, Ochiai Y, Harada T, Ueda T, Nakayama T, Aizawa S, Yoshino A. Interferon-β sensitizes human malignant melanoma cells to temozolomide-induced apoptosis and autophagy. International Journal of Oncology. 54: 1864-1874. PMID 30864696 DOI: 10.3892/ijo.2019.4743 |
0.333 |
|
| 2018 |
Sano EB, Wall CA, Hutchins PR, Miller SR. Ancient balancing selection on heterocyst function in a cosmopolitan cyanobacterium. Nature Ecology & Evolution. PMID 29335576 DOI: 10.1038/s41559-017-0435-9 |
0.309 |
|
| 2018 |
Ochiai Y, Sano E, Okamoto Y, Yoshimura S, Makita K, Yamamuro S, Ohta T, Ogino A, Tadakuma H, Ueda T, Nakayama T, Hara H, Yoshino A, Katayama Y. Efficacy of ribavirin against malignant glioma cell lines: Follow-up study. Oncology Reports. 39: 537-544. PMID 29251333 DOI: 10.3892/or.2017.6149 |
0.309 |
|
| 2015 |
Yamamuro S, Sano E, Okamoto Y, Ochiai Y, Ohta T, Ogino A, Natsume A, Wakabayashi T, Ueda T, Hara H, Nakayama T, Yoshino A, Katayama Y. Antitumorigenic effect of interferon-β by inhibition of undifferentiated glioblastoma cells. International Journal of Oncology. 47: 1647-54. PMID 26397698 DOI: 10.3892/ijo.2015.3165 |
0.362 |
|
| 2015 |
Yamamuro S, Okamoto Y, Sano E, Ochiai Y, Ogino A, Ohta T, Hara H, Ueda T, Nakayama T, Yoshino A, Katayama Y. Characterization of glioma stem-like cells from human glioblastomas. International Journal of Oncology. 47: 91-6. PMID 25955568 DOI: 10.3892/ijo.2015.2992 |
0.407 |
|
| 2014 |
Ogino A, Sano E, Ochiai Y, Yamamuro S, Tashiro S, Yachi K, Ohta T, Fukushima T, Okamoto Y, Tsumoto K, Ueda T, Yoshino A, Katayama Y. Efficacy of ribavirin against malignant glioma cell lines. Oncology Letters. 8: 2469-2474. PMID 25364409 DOI: 10.3892/ol.2014.2569 |
0.531 |
|
| 2012 |
Sano E, Tashiro S, Tadakuma H, Takei T, Ueda T, Tsumoto K. Type 1 IFN inhibits the growth factor deprived apoptosis of cultured human aortic endothelial cells and protects the cells from chemically induced oxidative cytotoxicity. Journal of Cellular Biochemistry. 113: 3823-34. PMID 22821369 DOI: 10.1002/jcb.24259 |
0.373 |
|
| 2012 |
Tashiro S, Tsumoto K, Sano E. Establishment of a microcarrier culture system with serial sub-cultivation for functionally active human endothelial cells. Journal of Biotechnology. 160: 202-13. PMID 22465290 DOI: 10.1016/j.jbiotec.2012.02.022 |
0.435 |
|
| Show low-probability matches. |